Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.

Patients with psoriasis have a higher risk for synovitis on imaging than healthy individuals, according to a systematic ...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating ...

One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...

A large cohort study of patients with psoriasis using wearable devices finds more exercise is associated with a lower risk ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

John McEnroe is on the call of the men's championship match at Wimbledon on Sunday. The iconic American tennis player, who ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...